253 related articles for article (PubMed ID: 37217845)
1. Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 model gene expression reversion.
Wilk EJ; Howton TC; Fisher JL; Oza VH; Brownlee RT; McPherson KC; Cleary HL; Yoder BK; George JF; Mrug M; Lasseigne BN
Mol Med; 2023 May; 29(1):67. PubMed ID: 37217845
[TBL] [Abstract][Full Text] [Related]
2. Pkd2 Deficiency in Embryonic Aqp2 + Progenitor Cells Is Sufficient to Cause Severe Polycystic Kidney Disease.
Tsilosani A; Gao C; Chen E; Lightle AR; Shehzad S; Sharma M; Tran PV; Bates CM; Wallace DP; Zhang W
J Am Soc Nephrol; 2024 Apr; 35(4):398-409. PubMed ID: 38254271
[TBL] [Abstract][Full Text] [Related]
3. The inhibition of MDM2 slows cell proliferation and activates apoptosis in ADPKD cell lines.
Patergnani S; Giattino A; Bianchi N; Giorgi C; Pinton P; Aguiari G
Biol Cell; 2023 Jan; 115(1):e2200037. PubMed ID: 36165233
[TBL] [Abstract][Full Text] [Related]
4. Polycystic kidney disease: novel insights into polycystin function.
Luo L; Roy S; Li L; Ma M
Trends Mol Med; 2023 Apr; 29(4):268-281. PubMed ID: 36805211
[TBL] [Abstract][Full Text] [Related]
5. Identification of pathological transcription in autosomal dominant polycystic kidney disease epithelia.
Friedrich S; Müller H; Riesterer C; Schüller H; Friedrich K; Wörner CL; Busch T; Viau A; Kuehn EW; Köttgen M; Hofherr A
Sci Rep; 2021 Jul; 11(1):15139. PubMed ID: 34301992
[TBL] [Abstract][Full Text] [Related]
6. Cilia and polycystic kidney disease.
Ma M
Semin Cell Dev Biol; 2021 Feb; 110():139-148. PubMed ID: 32475690
[TBL] [Abstract][Full Text] [Related]
7. Polycystin-2-dependent transcriptome reveals early response of autosomal dominant polycystic kidney disease.
Jung HJ; Dixon EE; Coleman R; Watnick T; Reiter JF; Outeda P; Cebotaru V; Woodward OM; Welling PA
Physiol Genomics; 2023 Nov; 55(11):565-577. PubMed ID: 37720991
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-Dependent Kinase 1 Activity Is a Driver of Cyst Growth in Polycystic Kidney Disease.
Zhang C; Balbo B; Ma M; Zhao J; Tian X; Kluger Y; Somlo S
J Am Soc Nephrol; 2021 Jan; 32(1):41-51. PubMed ID: 33046531
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.
Li A; Fan S; Xu Y; Meng J; Shen X; Mao J; Zhang L; Zhang X; Moeckel G; Wu D; Wu G; Liang C
J Cell Mol Med; 2017 Aug; 21(8):1619-1635. PubMed ID: 28244683
[TBL] [Abstract][Full Text] [Related]
10. Reduced ciliary polycystin-2 in induced pluripotent stem cells from polycystic kidney disease patients with PKD1 mutations.
Freedman BS; Lam AQ; Sundsbak JL; Iatrino R; Su X; Koon SJ; Wu M; Daheron L; Harris PC; Zhou J; Bonventre JV
J Am Soc Nephrol; 2013 Oct; 24(10):1571-86. PubMed ID: 24009235
[TBL] [Abstract][Full Text] [Related]
11. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.
Pastor-Soler NM; Li H; Pham J; Rivera D; Ho PY; Mancino V; Saitta B; Hallows KR
Am J Physiol Renal Physiol; 2022 Jan; 322(1):F27-F41. PubMed ID: 34806449
[TBL] [Abstract][Full Text] [Related]
12. Berberine slows cell growth in autosomal dominant polycystic kidney disease cells.
Bonon A; Mangolini A; Pinton P; Del Senno L; Aguiari G
Biochem Biophys Res Commun; 2013 Nov; 441(3):668-74. PubMed ID: 24184483
[TBL] [Abstract][Full Text] [Related]
13. Genetic reduction of cilium length by targeting intraflagellar transport 88 protein impedes kidney and liver cyst formation in mouse models of autosomal polycystic kidney disease.
Shao L; El-Jouni W; Kong F; Ramesh J; Kumar RS; Shen X; Ren J; Devendra S; Dorschel A; Wu M; Barrera I; Tabari A; Hu K; Haque N; Yambayev I; Li S; Kumar A; Behera TR; McDonough G; Furuichi M; Xifaras M; Lu T; Alhayaza RM; Miyabayashi K; Fan Q; Ajay AK; Zhou J
Kidney Int; 2020 Nov; 98(5):1225-1241. PubMed ID: 32610050
[TBL] [Abstract][Full Text] [Related]
14. Polycystin-1: a master regulator of intersecting cystic pathways.
Fedeles SV; Gallagher AR; Somlo S
Trends Mol Med; 2014 May; 20(5):251-60. PubMed ID: 24491980
[TBL] [Abstract][Full Text] [Related]
15. Exome Sequencing of a Clinical Population for Autosomal Dominant Polycystic Kidney Disease.
Chang AR; Moore BS; Luo JZ; Sartori G; Fang B; Jacobs S; Abdalla Y; Taher M; Carey DJ; Triffo WJ; Singh G; Mirshahi T
JAMA; 2022 Dec; 328(24):2412-2421. PubMed ID: 36573973
[TBL] [Abstract][Full Text] [Related]
16. Genetics May Predict Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
Sekine A; Hoshino J; Fujimaru T; Suwabe T; Mizuno H; Kawada M; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Mandai S; Chiga M; Kikuchi H; Ando F; Mori T; Sohara E; Uchida S; Sawa N; Takaichi K; Ubara Y
Am J Nephrol; 2020; 51(9):745-751. PubMed ID: 32784291
[TBL] [Abstract][Full Text] [Related]
17. Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
Spirli C; Mariotti V; Villani A; Fabris L; Fiorotto R; Strazzabosco M
J Hepatol; 2017 Mar; 66(3):571-580. PubMed ID: 27826057
[TBL] [Abstract][Full Text] [Related]
18. Prioritization of novel ADPKD drug candidates from disease-stage specific gene expression profiles.
Malas TB; Leonhard WN; Bange H; Granchi Z; Hettne KM; Van Westen GJP; Price LS; 't Hoen PAC; Peters DJM
EBioMedicine; 2020 Jan; 51():102585. PubMed ID: 31879244
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of transcription factor profiles in polycystic kidney disease (PKD): identification and validation of STAT3 and RUNX1 in the injury/repair response and PKD progression.
Formica C; Malas T; Balog J; Verburg L; 't Hoen PAC; Peters DJM
J Mol Med (Berl); 2019 Dec; 97(12):1643-1656. PubMed ID: 31773180
[TBL] [Abstract][Full Text] [Related]
20. Genetic Mechanisms of ADPKD.
Kim DY; Park JH
Adv Exp Med Biol; 2016; 933():13-22. PubMed ID: 27730431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
